%0 Journal Article
%T The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma.
%A Rathi VK
%A Soler ZM
%A Schlosser RJ
%A Workman AD
%A Chapurin N
%A Rowan NR
%A Dusetzina SB
%J Int Forum Allergy Rhinol
%V 14
%N 7
%D 2024 Jul 11
%M 38465800
%F 5.426
%R 10.1002/alr.23344
%X <B>CONCLUSIONS: </B>In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60%.